Ubtech Robotics Draws Upgraded Analyst Targets as Consumer Humanoid Bet Moves to Delivery Phase

Wall Street analysts sharply raise Ubtech targets; BofA and JPMorgan project steep delivery jump for consumer humanoids, but pre-orders and mass production risks remain.

Wall Street analysts have sharply raised their expectations for Ubtech Robotics, projecting a steep jump in deliveries of the company's new consumer humanoid line and propelling the stock to its biggest single-day gain since April. Shares in the Chinese robotics firm climbed 13.21% on Friday to €12.00, putting the weekly advance at 16.64% and reversing a slide during the first half of the week that had dragged the stock to €10.50.

BofA Securities lifted its price target to HK$162 and boosted revenue forecasts for 2026 through 2028 by 15%, 19% and 20% respectively. The bank now expects Ubtech's net loss to narrow to just 209 million renminbi this year, with profitability arriving in 2027. JPMorgan went further, raising its target to HK$161 on the back of a dramatically revised delivery outlook: instead of the previously estimated 7,000 to 8,000 units, the bank now expects roughly 20,000 hyper-bionic humanoids to ship in 2026. JPMorgan cautioned that further delivery metrics are needed before it fully endorses the new target.

The optimism stems from Ubtech's aggressive pivot to consumer robotics. The company unveiled its UWORLD U1 series on 30 June 2026, targeting companionship, elderly care, reception and tourism roles. Pre-orders reached 13,361, though the models carry price tags between 119,800 and 990,000 yuan — a level that puts them out of reach for most mass-market households. Many pre-orders require only a deposit, not a firm purchase commitment, leaving real demand uncertain.

The operational challenge is equally daunting. Ubtech has never demonstrated mass production at this scale. First deliveries are scheduled for 16 September 2026, with the entire batch due to be shipped by year-end. Chinese media have also questioned whether the U1 Ultra's pricing fits its target audience and whether the "companion" concept truly taps into the loneliness economy or remains a narrative without purchasing-power backing.

Competition is heating up. Unitree Robotics, which had already delivered over 5,500 humanoids profitably in 2025, secured a Shanghai STAR Market IPO on 1 June, raising 4.2 billion renminbi. Ubtech, by contrast, remains deep in the red: its 2025 net loss stood at 703.2 million yuan, and the company has burned nearly 5 billion yuan over the past five years.

A counterweight to those concerns is Ubtech's established industrial robotics business. Revenue from full-sized humanoids for factory use surged 2,204% year-on-year in 2025, making it the group's largest revenue source. A partnership with Siemens Industrial Software, inked in March, aims to digitise manufacturing, while a verification phase with Hitachi China for smart-factory solutions began in May.

Yet the financial picture remains fragile. Ubtech has historically funded itself through capital increases, and the pending H Share Full Circulation — which would allow trading of 5.45 million currently non-tradable domestic shares in Hong Kong — could either boost liquidity or lead to further dilution if additional capital is needed. The process still requires final regulatory approvals from mainland China and Hong Kong.

Technically, the stock is trading near its 50-day moving average of €11.96 and its 100-day average of €12.13, and the 14-day relative strength index sits at 52.5 — a neutral reading. Annualised 30-day volatility remains extreme at 85.82%. Year to date, Ubtech shares are still down 17.92%, and they stand nearly 30% below the January high of €17.00. The next key catalyst comes on 16 September, when the first U1 deliveries are due. A smooth rollout would provide tangible evidence of mass-production capability; any delay would likely test the market's newly bullish conviction.